Selected article for: "development process and drug target"
Author: Vicenti, Ilaria; Zazzi, Maurizio; Saladini, Francesco
Title: SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
  • Cord-id: 39bgic7k
  • Document date: 2021_3_3
    • ID: 39bgic7k
    Snippet: Introduction: The current SARS-CoV-2 pandemic urgently demands for both prevention and treatment strategies. RNA-dependent RNA-polymerase (RdRp), which has no counterpart in human cells, is an excellent target for drug development. Given the time-consuming process of drug development, repurposing drugs approved for other indications or at least successfully tested in terms of safety and tolerability, is an attractive strategy to rapidly provide an effective medication for severe COVID-19 cases.
    Document: Introduction: The current SARS-CoV-2 pandemic urgently demands for both prevention and treatment strategies. RNA-dependent RNA-polymerase (RdRp), which has no counterpart in human cells, is an excellent target for drug development. Given the time-consuming process of drug development, repurposing drugs approved for other indications or at least successfully tested in terms of safety and tolerability, is an attractive strategy to rapidly provide an effective medication for severe COVID-19 cases. Areas covered: The currently available data and upcoming studies on RdRp which can be repurposed to halt SARS-CoV-2 replication, are reviewed. Expert opinion: Drug repurposing and design of novel compounds are proceeding in parallel to provide a quick response and new specific drugs, respectively. Notably, the proofreading SARS-CoV-2 exonuclease activity could limit the potential for drugs designed as immediate chain terminators and favor the development of compounds acting through delayed termination. While vaccination is awaited to curb the SARS-CoV-2 epidemic, even partially effective drugs from repurposing strategies can be of help to treat severe cases of disease. Considering the high conservation of RdRp among coronaviruses, an improved knowledge of its activity in vitro can provide useful information for drug development or drug repurposing to combat SARS-CoV-2 as well as future pandemics.

    Search related documents:
    Co phrase search for related documents
    • acceptable safety and active site: 1
    • acceptable safety and acute ards respiratory distress syndrome: 1
    • acceptable safety and acute infection: 1
    • acceptable safety and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • accessory protein and active site: 1, 2
    • accessory protein and acute ards respiratory distress syndrome: 1
    • accessory protein and acute infection: 1, 2, 3, 4, 5, 6
    • accessory protein and acute lung injury: 1
    • accessory protein and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active form and acute ards respiratory distress syndrome: 1
    • active form and acute infection: 1, 2, 3
    • active form and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • active molecule and acute sars cov respiratory syndrome coronavirus: 1, 2
    • active site and acute ards respiratory distress syndrome: 1, 2
    • active site and acute infection: 1, 2, 3, 4, 5, 6
    • active site and acute lung injury: 1, 2
    • active site and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and adenosine analog: 1, 2, 3
    • activity lack and acute ards respiratory distress syndrome: 1